# Non-invasive cancer detection and residual disease monitoring by cell-free nucleic acid from saliva

> **NIH NIH R43** · NORD BIO INC · 2024 · $295,757

## Abstract

Cancer is one of the leading causes of death globally and detection, continuous monitoring and effective
treatment are critical for improving patient outcomes. Currently, cancer diagnosis and genomic analysis for
personalized treatment often require invasive procedures such as biopsies, which can be costly,
time-consuming, and carry risks to the patient. An alternative, less invasive method for detecting cancer is the
detection of tumor-derived circulating free DNA (cfDNA) in biological fluids such as blood. This method has
shown promise as to detect cancer as it reflects the genetic changes, such as mutations present in the tumor
tissue. In addition to primary cancer diagnosis, highly sensitive disease monitoring is crucial in the minimal
residual disease (MRD) setting, which refers to the low-level presence of cancer cells in the body after surgery
and treatment and can predict cancer recurrence and overall survival and is therefore of great interest to
clinicians as a biomarker. Saliva is a biological fluid that has been explored as a source of cfDNA and blood
cells but has not yet been utilized as a basis for assay development due to a lack of characterization of cfDNA
levels and validation of consistent tumor DNA presence. As the efficiency of monitoring residual disease and
cancer detection relies on frequent, repetitive sampling of cfDNA from the patient, saliva represents an
attractive modality as it is an easy-to-obtain sample type, including in an at-home setting. In this proposal, we
aim to develop and evaluate an assay to detect and monitor the level of cfDNA from tumor in saliva and
compare the sensitivity of detection to cfDNA obtained from plasma/blood for patients with head and neck
squamous cell carcinoma (HNSCC), where we recently described the evolutionary trajectories and early vs.
late genomic driver event emergence, in both HPV+ and HPV- HNSCC. Despite its high prevalence as the
sixth most frequent cancer worldwide, most HNSCC patients continue to be diagnosed with late-stage cancer,
underscoring the need for sensitive early detection as well as disease monitoring for treatment response. To
achieve the necessary degree of sensitivity for what is often a low tumor DNA fraction in saliva, we will use
duplex sequencing to minimize sequencing errors, develop algorithms and machine learning models for
genomic analysis of cfDNA, and increase sensitivity by integrating signal with DNA methylation data. As a
result of this Phase I proposal, we will investigate the use of cfDNA from saliva samples, compare it with
plasma cfDNA testing, develop the experimental and computational methodology for saliva cancer genomic
tests, quantify the cost-effectiveness of this approach, and aim to develop a reliable, non-invasive method for
detecting and monitoring cancer.

## Key facts

- **NIH application ID:** 10921095
- **Project number:** 1R43CA285075-01A1
- **Recipient organization:** NORD BIO INC
- **Principal Investigator:** Ignaty Leshchiner
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $295,757
- **Award type:** 1
- **Project period:** 2024-07-15 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10921095

## Citation

> US National Institutes of Health, RePORTER application 10921095, Non-invasive cancer detection and residual disease monitoring by cell-free nucleic acid from saliva (1R43CA285075-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10921095. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*